Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
5.22
+0.17 (3.37%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Elicio Therapeutics Employees
Elicio Therapeutics had 32 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
32
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,621,813
Market Cap
83.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32 | 0 | - |
| Dec 31, 2023 | 32 | 9 | 39.13% |
| Dec 31, 2022 | 23 | -1 | -4.17% |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Dec 31, 2020 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
ELTX News
- 7 days ago - Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires - GlobeNewsWire
- 23 days ago - Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 weeks ago - Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewsWire
- 2 months ago - Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data - Seeking Alpha
- 3 months ago - Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 - GlobeNewsWire
- 5 months ago - Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 months ago - Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting - GlobeNewsWire